Estimates of clinically useful measures in competing risks survival analysis

被引:24
作者
Ambrogi, Federico [1 ]
Biganzoli, Elia [1 ,2 ]
Boracchi, Patrizia [1 ]
机构
[1] Univ Milan, Ist Stat Med & Biometria GA Maccacaro, I-20133 Milan, Italy
[2] Ist Nazl Studio & Cura Tumori, Div Stat & Biometria, I-20133 Milan, Italy
关键词
competing risks; clinically useful measures; pseudo-values; generalized estimating equations;
D O I
10.1002/sim.3455
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Competing risks occur frequently in follow-up clinical studies. To assess treatment or covariate effects, measures of clinical impact based on crude cumulative incidence should be considered, such as relative risks or the absolute risk reduction. In this work, transformation models through suitable link functions provide a straightforward approach to obtain point and interval estimates of such measures. An extension of the Klein and Andersen proposal, based on pseudo-values, is considered. Non-additive effects were tested by interactions between baseline (spline function on time) and covariates. The methods are applied to the evaluation of the impact of axillary lymph node nanometastases on metastatic relapse of breast cancer patients. Further, a literature data set on prostate cancer was used for illustration. Copyright (C) 2008 John Wiley & Sons,
引用
收藏
页码:6407 / 6425
页数:19
相关论文
共 43 条
[1]   Calculating the number needed to treat for trials where the outcome is time to an event [J].
Altman, DG ;
Andersen, PK .
BRITISH MEDICAL JOURNAL, 1999, 319 (7223) :1492-1495
[2]   Confidence intervals for the number needed to treat [J].
Altman, DG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7168) :1309-1312
[3]   Generalised linear models for correlated pseudo-observations, with applications to multi-state models [J].
Andersen, PK ;
Klein, JP ;
Rosthoj, S .
BIOMETRIKA, 2003, 90 (01) :15-27
[4]  
BARROS AJ, 2003, BMC MED RES METHODOL, V21, P203
[5]   Calculating confidence intervals for the number needed to treat [J].
Bender, R .
CONTROLLED CLINICAL TRIALS, 2001, 22 (02) :102-110
[6]  
BORACCHI P, 1990, TUMORI J, V76, P1
[7]  
BYAR DP, 1980, B CANCER, V67, P477
[8]  
*CA, 2004, CA-CANCER J CLIN, V54, P123
[9]  
CAREY VJ, 2004, GEN ESTIMATION EQUAT
[10]   Interpreting measures of treatment effect in cancer clinical trials [J].
Case, LD ;
Kimmick, G ;
Paskett, ED ;
Lohman, K ;
Tucker, R .
ONCOLOGIST, 2002, 7 (03) :181-187